Ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam activities against multidrug-resistant Enterobacterales from United States Medical Centers (2018–2022)
Author:
Funder
AbbVie
Publisher
Elsevier BV
Subject
Infectious Diseases,Microbiology (medical),General Medicine
Reference24 articles.
1. Progress in the fight against multidrug-resistant bacteria? A review of U.S. Food and Drug Administration-approved antibiotics, 2010-2015;Deak;Ann Intern Med,2016
2. Meropenem-vaborbactam as salvage therapy for ceftazidime-avibactam-, cefiderocol-resistant ST-512 Klebsiella pneumoniae-producing KPC-31, a D179Y variant of KPC-3;Tiseo;Open Forum Infect Dis,2021
3. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis;Cassini;Lancet Infect Dis,2019
4. Time to appropriate antibiotic therapy is a predictor of outcome in patients with bloodstream infection caused by KPC-producing Klebsiella pneumoniae;Falcone;Crit Care,2020
5. Clinical and microbiological analysis of risk factors for mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia;Son;Open Forum Infect Dis,2020
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. In Vitro Activity of “Old” and “New” Antimicrobials against the Klebsiella pneumoniae Complex;Antibiotics;2024-01-26
2. Reviewing novel treatment options for carbapenem-resistant Enterobacterales;Expert Review of Anti-infective Therapy;2024-01-05
3. Worldwide trend discovery of structural and functional relationship of metallo-β-lactamase for structure-based drug design: A bibliometric evaluation and patent analysis;International Journal of Biological Macromolecules;2024-01
4. Real-world in vitro activity of newer antibiotics against Enterobacterales and Pseudomonas aeruginosa , including carbapenem-non-susceptible and multidrug-resistant isolates: a multicenter analysis;Microbiology Spectrum;2023-12-12
5. Approaches to Testing Novel β-Lactam and β-Lactam Combination Agents in the Clinical Laboratory;Antibiotics;2023-12-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3